

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Shanghai HeartCare Medical Technology
Corporation Limited**

上海心瑋醫療科技股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 6609)*

POSITIVE PROFIT ALERT

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review of the Group’s unaudited consolidated management accounts for the year ended December 31, 2025 (the “**Reporting Period**”) and the information currently available to the Board, the revenue of the Group is expected to be within the range of approximately RMB400.0 million to RMB410.0 million for the Reporting Period, representing an increase of at least 43.9%, from the revenue of RMB277.9 million for the year ended December 31, 2024. The Group also expects to record the profit before tax of approximately RMB80.0 million for the Reporting Period, representing a significant increase compared to the net loss before tax of RMB12.0 million for the year ended December 31, 2024. The anticipated turnaround to profit was mainly attributable to:

- the increase in revenue, which is driven by:
 - (1) the launch of new products and technologies for ischemic stroke and the increasing market share of ischemic stroke products;

- (2) the scaled commercialization of intracranial stents and higher sales of other products for hemorrhagic stroke; and
- (3) the continued growth in the sales of interventional access products; and

– the reduction in the Group’s expense ratio resulting from the effective cost control measures of cost of sales and administrative costs.

As of the date of this announcement, the Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2025. The information contained in this announcement is only a preliminary assessment by the Board based on the unaudited consolidated management accounts of the Group for the Reporting Period currently available to the Company, and is not based on any figures or information which have been reviewed or confirmed by the audit committee of the Board, or reviewed or audited by the independent auditors of the Company. The actual results of the Group for the Reporting Period may differ from those disclosed in this announcement. They shall not be taken as a measure or indication of the Group’s current or future operating or financial performance nor shall they be taken as a representation by the Group of the corresponding figures as may be provided in due course in the Company’s annual results announcement for the Reporting Period, which is expected to be published by the end of March 2026 in accordance with the requirements of the Listing Rules. As such, the above figures are provided for Shareholders’ and investors’ reference only. Shareholders and potential investors are advised to read carefully the annual results announcement of the Company for the Reporting Period.

The Group expects to record the adjusted profit before tax of approximately RMB77.0 million for the Reporting Period, representing a significant increase from the adjusted net loss before tax of RMB11.5 million for the year ended December 31, 2024. The Company defines adjusted net profit before tax as net profit before tax excluding the impact of: (i) equity-settled share award expenses; (ii) fair value gains on financial assets at fair value through profit or loss in relation to the Group’s investment in unlisted funds. The Company believes that the above adjusted Non-International Financial Reporting Standards (“**Non-IFRS**”) financial measures are useful for understanding and assessing underlying business performance and operating trends of the Company by the Company’s management and investors, and that the Company’s management and investors may benefit from referring to these adjusted financial measures in assessing the Group’s financial performance by eliminating the impact of certain unusual and non-recurring items that the Group does not consider indicative of the performance of the Group’s business. However, the use of these Non-IFRS financial measures has limitation as an analytical tool, and the presentation of these Non-IFRS financial measures is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with the International Financial Reporting Standards.

Shareholders and potential investors of the Company are advised to exercise due caution when dealing in the securities of the Company. When in doubt, Shareholders and potential investors are advised to seek professional advice from professional or financial advisers.

By order of the Board

Shanghai HeartCare Medical Technology Corporation Limited

WANG Guohui

Chairman of the Board

Shanghai, January 20, 2026

As at the date of this announcement, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui, Mr. Chen Shaoxiong and Mr. Chen Gang; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.